Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aurinia Pharm Ord
(NQ:
AUPH
)
6.760
+0.110 (+1.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aurinia Pharm Ord
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Aurinia Pharmaceuticals: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
May 04, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
May 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tesla, AMD, Ford, Starbucks, Aurinia Pharma: Why These 5 Stocks Are Drawing Investors' Attention Today
May 02, 2023
Via
Benzinga
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
May 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
April 11, 2023
Investors appear to be cheering another patent win by the company.
Via
The Motley Fool
Aurinia Pharmaceuticals's Return On Capital Employed Insights
March 03, 2023
Via
Benzinga
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
May 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
April 28, 2023
From
Aurinia
Via
Business Wire
3 Biotechs That Might Get Bought Out in 2023
April 26, 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year.
Via
The Motley Fool
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
April 25, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Preview: Aurinia Pharmaceuticals's Earnings
February 27, 2023
Via
Benzinga
Why Shares of Aurinia Pharmaceuticals Soared This Week
January 06, 2023
A patent settlement and improved financials sent the stock soaring.
Via
The Motley Fool
Second Quarter Outlook For Biotech Stocks
April 25, 2023
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.
Via
Talk Markets
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
April 24, 2023
Via
Benzinga
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
April 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
April 11, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
April 11, 2023
The gains these stocks notched in the first few months of the year could be the beginning of a much longer bull run.
Via
The Motley Fool
What's Going On With Aurinia Pharmaceuticals Stock Wednesday?
April 05, 2023
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher Wednesday after the company announced "promising results" from its AURORA
Via
Benzinga
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
April 05, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
What's Going On With Aurinia Pharmaceuticals Stock Today?
February 28, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales fig
Via
Benzinga
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
February 28, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
February 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
February 07, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
These 2 Healthcare Stocks Have Doubled in 2023
February 01, 2023
Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.
Via
MarketBeat
Aurinia Announces PTAB Has Terminated Inter Partes Review
January 25, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
January 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.